The Oregon Health Authority has finalized the first subset of rules for the legal psilocybin services that will be available next year.
The full set of guideline, which cover psilocybin production methods and facilitator training requirements, can be found here.
A second committee meeting will take place in the Fall to establish the remainder of the rules.
Ceruvia Lifesciences submitted an application to study psilocybin as a treatment for obsessive-compulsive disorder (OCD) in a Phase 2 trial.
Preliminary findings suggest that psilocybin causes a “rapid and robust improvement in OCD symptoms with a sustained effect,” according to the press release.
The trial, which will be led by Yale researchers later this year if approval is granted, will determine if these findings hold true when psilocybin is compared to an active placebo.
In his opening speech at the Catalyst Psychedelics Summit, Canadian Senator Larry Campbell shared his fascinating (yet slightly disturbing) experience with microdosing.
The 74-year-old politician had been suffering from depression and PTSD for ages when his mental health suddenly started improving out of nowhere.
When Larry told his wife the good news, she admitted that she’d been spiking his morning coffee with a bit of psilocybin for the past two weeks 😲
While we don’t condone drugging people without their knowledge, her experiment revealed some important anecdotal evidence – the benefits that Larry experienced must have been from the psilocybin itself and not a result of the placebo effect!
This quarter, MindMed (MNMD) will begin a Phase 2a trial to see if its non-hallucinogenic ibogaine formulation (MM-110) can treat opioid withdrawal.
In preclinical research, MM-110 showed “multi-day reductions in opioid self-administration” after a single dose.
In the Phase 1 trial, MM-110 was found to be safe and well-tolerated at varying doses. Some participants received two 325 mg doses on a single day while others received a 90 mg dose twice daily for 7 days.
Let’s see what Phase 2 reveals!
After piloting the program for 9 months, Novamind’s group ketamine therapy for frontline workers is now available to the public.
The 6-week program is designed to help healthcare workers, police officers, firefighters and paramedics work through trauma with the support of their peers.
“The greatest improvement has been my PTSD… Even when I do feel myself reacting, I feel I have more awareness and I am able to better regulate,” says one of the participants of the pilot program.
We bet you never knew that these animals could make you trip:
The more you know!
atai Life Sciences (ATAI) announced Q1 highlights including a $36.9M net loss and $335M in cash, which is projected to fund operations until the end of 2023. The company plans to progress 10 compounds through clinical development, which are supported by a total of 171 issued patents and 49 pending patents.
MindMed (MNMD) announced Q1 results including a $18.5M net loss and a $120.5M cash position, enough to support operations into 2024.
Mydecine (MYCO) announced a $5.6M net loss and $264.7K cash position as of the end of Q1 (March 31), but has since raised an additional $1.65M in financing.
After several unsuccessful depression treatments, a patient in Quebec will finally get to try psilocybin therapy through the Special Access Program (SAP), marking the first legal psilocybin treatment in the province.
Numinus Wellness (NUMI) received Health Canada approval to administer the treatment at its Montreal clinic. It will be the company’s first treatment outside of a clinical trial setting.
Hopefully we’ll start seeing more wins like this thanks to TheraPsil, a non-profit that launched an initiative to make it easier for patients to access psilocybin through the SAP.
The initiative, called Project Solace, will secure a safe supply of psilocybin from HAVN Life (HAVN) and other licensed dealers and collect data on treatment outcomes to support policy change.
